Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2015

01-04-2015 | Research Article

Different frequencies and effects of ABCB1 T3435C polymorphism on clinical and laboratory features of B cell chronic lymphocytic leukemia in Kurdish patients

Authors: Farzad Maroofi, Sabrieh Amini, Daem Roshani, Bayazid Ghaderi, Mohammad Abdi

Published in: Tumor Biology | Issue 4/2015

Login to get access

Abstract

Finding the effects of gene polymorphism on cancer pathogenesis is very desirable. The ATP-binding cassette is involved in drug metabolism, and the polymorphism of this gene may be an important risk factor in B cell chronic lymphocytic leukemia (B-CLL) or progression and/or response to chemotherapy agents. For the first time, the present study was aimed to evaluate the probable effects of ABCB1 T3435C polymorphism on clinical and laboratory features of Kurdish patients with B-CLL. This descriptive analytical case-control study was performed on 50 B-CLL patients and 100 healthy subjects. Serum levels of beta-2-microglobulin (B2M) and lactate dehydrogenase (LDH) and blood WBC, RBC, Plt and ESR were measured. The T3435C polymorphism of the ABCB1 gene was determined by PCR-RFLP. Concentration of serum and blood markers was significantly higher in the malignant group than in the benign subjects. The CC genotype had the highest frequency (66 %) in the patient groups. There are no significant differences between the genotypes and type of treatment. Our results demonstrate the high frequency of C allele of ABCB1 T3435C in B-CLL patients with Kurdish ethnicity. We also show that this polymorphism has a significant risk factor in B-CLL. However, the effect of this polymorphism on clinical and laboratory characteristics of B-CLL patients was not significant.

Literature
  1. Hamblin TJ. Achieving optimal outcomes in chronic lymphocytic leukaemia. Drugs. 2001;61(5):593–611.View ArticlePubMed
  2. Gill S, Carney D, Ritchie D, Wolf M, Westerman D, Prince HM, et al. The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy. Ann Oncol. 2010;21(2):331–4.View ArticlePubMed
  3. Houlston RS, Catovsky D, Yuille MR. Genetic susceptibility to chronic lymphocytic leukemia. Leuk. 2002;16(6):1008–14.View Article
  4. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–56.View ArticlePubMedPubMed Central
  5. Zent CS, Call TG, Hogan WJ, Shanafelt TD, Kay NE. Update on risk-stratified management for chronic lymphocytic leukemia. Leuk Lymphoma. 2006;47(9):1738–46.View ArticlePubMed
  6. Breier A, Barancik M, Sulova Z, Uhrik B. P-glycoprotein—implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets. 2005;5(6):457–68.View ArticlePubMed
  7. Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut. 2003;52(5):759–66.View ArticlePubMedPubMed Central
  8. Zintzaras E. Is there evidence to claim or deny association between variants of the multidrug resistance gene (MDR1 or ABCB1) and inflammatory bowel disease? Inflamm Bowel Dis. 2012;18(3):562–72.View ArticlePubMed
  9. Friedenberg WR, Spencer SK, Musser C, Hogan TF, Rodvold KA, Rushing DA, et al. Multi-drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma. 1999;34(1–2):171–8.View ArticlePubMed
  10. Rosenwald A. Multi-drug resistance in B-cell chronic lymphocytic leukemia (B-CLL): a feature of B-CLL sub-sets with poor prognosis genetic alterations? Leuk Lymphoma. 2006;47(11):2263–4.View ArticlePubMed
  11. Sparrow RL, Hall FJ, Siregar H, Van der Weyden MB. Common expression of the multidrug resistance marker P-glycoprotein in B-cell chronic lymphocytic leukaemia and correlation with in vitro drug resistance. Leuk Res. 1993;17(11):941–7.View ArticlePubMed
  12. Webb M, Brun M, McNiven M, Le Couteur D, Craft P. MDR1 and MRP expression in chronic B-cell lymphoproliferative disorders. Br J Haematol. 1998;102(3):710–7.View ArticlePubMed
  13. Bosch F, Ferrer A, Lopez-Guillermo A, Gine E, Bellosillo B, Villamor N, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol. 2002;119(4):976–84.View ArticlePubMed
  14. Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98(8):2319–25.View ArticlePubMed
  15. Robak T, Blonski JZ, Kasznicki M, Gora-Tybor I, Dwilewicz-Trojaczek J, Boguradzki P, et al. Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. Leuk. 2001;15(10):1510–6.View Article
  16. Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2003;97(7):1711–20.View ArticlePubMed
  17. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenet. 2001;11(3):217–21.View Article
  18. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97(7):3473–8.View ArticlePubMedPubMed Central
  19. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70(2):189–99.View ArticlePubMed
  20. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219–34.PubMed
  21. Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood. 2006;107(3):859–61.View ArticlePubMed
  22. Hoellein A, Decker T, Bogner C, Oelsner M, Hauswald S, Peschel C, et al. Expression of multidrug resistance-associated ABC transporters in B-CLL is independent of ZAP70 status. J Cancer Res Clin Oncol. 2010;136(3):403–10.View ArticlePubMed
  23. Penna G, Allegra A, Alonci A, Aguennouz M, Garufi A, Cannavo A, et al. MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: an impact on susceptibility and prognosis. Med Oncol (Northwood Lond Engl). 2011;28(4):1549–54.View Article
  24. Goreva OB, Grishanova AY, Mukhin OV, Domnikova NP, Lyakhovich VV. Possible prediction of the efficiency of chemotherapy in patients with lymphoproliferative diseases based on MDR1 gene G2677T and C3435T polymorphisms. Bull Exp Biol Med. 2003;136(2):183–5.View ArticlePubMed
  25. Jamroziak K, Balcerczak E, Calka K, Piaskowski S, Urbanska-Rys H, Salagacka A, et al. Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. Leuk Res. 2009;33(2):332–5.View ArticlePubMed
  26. Rochlitz CF, de Kant E, Neubauer A, Heide I, Bohmer R, Oertel J, et al. PCR-determined expression of the MDR1 gene in chronic lymphocytic leukemia. Ann Hematol. 1992;65(6):241–6.View ArticlePubMed
  27. Li YH, Wang YH, Li Y, Yang L. MDR1 gene polymorphisms and clinical relevance. Yi chuan xue bao = Acta genetica Sinica. 2006;33(2):93–104.PubMed
  28. Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol. 2003;14(7):1889–96.View ArticlePubMed
  29. Bernal ML, Sinues B, Fanlo A, Mayayo E. Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. Ther Drug Monit. 2003;25(1):107–11.View ArticlePubMed
  30. Jamroziak K, Balcerczak E, Mlynarski W, Mirowski M, Robak T. Distribution of allelic variants of functional C3435T polymorphism of drug transporter MDR1 gene in a sample of Polish population. Pol J Pharmacol. 2002;54(5):495–500.PubMed
  31. Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterol. 2003;124(1):26–33.View Article
  32. Balram C, Sharma A, Sivathasan C, Lee EJ. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br J Clin Pharmacol. 2003;56(1):78–83.View ArticlePubMedPubMed Central
  33. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res. 2001;18(10):1400–4.View ArticlePubMed
  34. Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci. 2000;25(1):1–6.View ArticlePubMed
  35. Mizutani T, Masuda M, Nakai E, Furumiya K, Togawa H, Nakamura Y, et al. Genuine functions of P-glycoprotein (ABCB1). Curr Drug Metab. 2008;9(2):167–74.View ArticlePubMed
  36. Rund D, Azar I, Shperling O. A mutation in the promoter of the multidrug resistance gene (MDR1) in human hematological malignancies may contribute to the pathogenesis of resistant disease. Adv Exp Med Biol. 1999;457:71–5.View ArticlePubMed
Metadata
Title
Different frequencies and effects of ABCB1 T3435C polymorphism on clinical and laboratory features of B cell chronic lymphocytic leukemia in Kurdish patients
Authors
Farzad Maroofi
Sabrieh Amini
Daem Roshani
Bayazid Ghaderi
Mohammad Abdi
Publication date
01-04-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2914-9

Other articles of this Issue 4/2015

Tumor Biology 4/2015 Go to the issue

Research Article

RETRACTED ARTICLE: Diagnostic investigations of canine prostatitis incidence together with benign prostate hyperplasia, prostate malignancies, and biochemical recurrence in high-risk prostate cancer as a model for human study

Research Article

The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC)

Research Article

LASS2/TMSG1 inhibits growth and invasion of breast cancer cell in vitro through regulation of vacuolar ATPase activity

Research Article

MicroRNA-145 as ideal biomarker for the diagnosis of various carcinomas

Research Article

Association between GSTM1 and GSTT1 polymorphisms and esophageal squamous cell carcinoma: results from a case-control study in Kashmir, India

Review

COL11A1/(pro)collagen 11A1 expression is a remarkable biomarker of human invasive carcinoma-associated stromal cells and carcinoma progression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits